Wanchen Biotechnology released its performance for the first three quarters, with a net profit attributable to the parent company of 855 million yuan, an increase of 917.04%
Wanchen Biotechnology released its Q3 2025 report, with operating revenue for the first three quarters reaching 36.562 billion yuan, a year-on-year increase of 77.37%; net profit attributable to shareholders was 855 million yuan, a year-on-year increase of 917.04%; net profit excluding non-recurring gains and losses was 806 million yuan, a year-on-year increase of 955.27%; basic earnings per share were 4.684 yuan
According to the Zhitong Finance APP, Wanchen Biotechnology (300972.SZ) released its third-quarter report for 2025. The company's operating revenue for the first three quarters was 36.562 billion yuan, a year-on-year increase of 77.37%. The net profit attributable to shareholders of the listed company was 855 million yuan, a year-on-year increase of 917.04%. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 806 million yuan, a year-on-year increase of 955.27%. The basic earnings per share were 4.684 yuan
